Innate Pharma SA announced that four abstracts with Innate’s drug candidates have been accepted for the European Association of Hematology 2024 Congress, taking place June 13-16, 2024 in Madrid, Spain. Two abstracts on SAR443579 (IPH6101), ANKET® platform lead asset, a trifunctional a...
not just at this Congress. There has been enormous scientific production and great results, with Chinese scholars always being very innovative in bringing new medicines and strategies to the forefront. It is essential that we cont...
not just at this Congress.There has been enormous scientific production and great results,with Chinese scholars always being very innovative in bringing new medicines and strategies to the forefront.It is essential that we continue to collaborate and share knowledge for the benefit of all patients...
Additionally, 43 abstracts will be presented at the European Hematology Association (EHA) 2024 Congress the following week. Eighteen oral presentations across both meetings include new data from pivotal trials and updated clinical data in ...
Antonio Almeida:Chinese scientific hematology has made a huge contribution to science worldwide, not just at this Congress. There has been enormous scientific production and great results, with Chinese scholars always being very innovative in bringing new medicines and strategies to the forefront. It ...
◆ 下次会议:2024年第29届欧洲血液学年会(EHA2024) ◆ 会议简介: 2023年第28届欧洲血液学大会/年会(28th EHA Congress)将于2023年6月8日至11日在德国法兰克福举行,会议由欧洲血液学会(EHA)主办。欧洲血液年会(EHA年会)是全球血液学领域规模最大的国际会议之一,于每年的6月在欧洲一个主要城市举行。EHA大会主题涵...
June 3, 2025 (15:30 CEST)Late-breaking abstracts available online June 12-15, 2025EHA2025 Congress, Milan, Italy Ends June 15, 2025, 13:00 (CEST)Deadline for Late HYBRID registration fee Ends June 30, 2025, 13:00 (CEST)Deadline for Late VIRTUAL registration fee ...
Shattuck Labs, Inc. today announced that it will host an investor call for an interim safety and efficacy update from the Phase 1B dose expansion clinical trial of SL-172154 with AZA in HR-MDS and TP53m AML, being presented at the EHA 2024 ...
--Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of three abstracts submitted to the European Hematology Association Congress, to be held
today announced that it will host an investor call for an interim safety and efficacy update from the Phase 1B dose expansion clinical trial of SL-172154 with AZA in HR-MDS and TP53m AML, being presented at the EHA 2024 Congress. The event will feature lead investigator, Dr. Naval G. ...